×



Make an Appointment

HUMAN ONCOLOGY & PATHOGENESIS PROGRAM

Madest all Batile Otentoneen & Treatment

The Yu Chen Lab

ABOUT US

Refer a Patient

Our mission, vision & core values

Leadership

History


Equality, diversity & inclusion

Annual report

Give to MSK

_ - - _ - - - - - - - - -


The Yu Chen Lab




Yu Chen, MD, PhD

The major goal of my laboratory is to understand how critical transcription factors mediate prostate cancer oncogenesis. Prostate cancers uniquely harbor very few mutations in well-known driver oncogenes (e.g., RAS, BRAF, etc.). Instead, they are characterized by aberrations in transcription factors, including the androgen receptor (AR) and ETS family transcription factors. These oncogenic transcription factors regulate a transcriptional program that determines cellular lineage, specifies the responses to external stimuli, and contributes to the oncogenic cellular context in prostate cancer. Our long-term goal is to generate an integrative understanding of how transcription factors normally guide the prostate lineage determination and how their deregulation leads to cancer. In addition, using biochemistry and genetic screens, we are pursuing ways to target the activity of these transcription factors that can lead to drug discovery.

The Yu Chen Lab 2/8



Featured News



MSK Scientists Identify New — and Very Common — Subtype of Prostate Cancer

The findings could pave the way toward more targeted treatments for the disease.

Publications Highlights

Tang F, Xu D, Wang S, Wong CK, Martinez-Fundichely A, Lee CJ, Cohen S, Park J, Hill CE, Eng K, Bareja R, Han T, Liu EM, Palladino A, Di W, Gao D, Abida W, Beg S, Puca L, Meneses M, de Stanchina E, Berger MF, Gopalan A, Dow LE,

The Yu Chen Lab 3/8

Mosquera JM, Beltran H, Sternberg CN, Chi P, Scher HI, Sboner A, Chen Y, Khurana E. <u>Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets</u>. Science. 2022 May 27;376(6596):eabe1505. doi: 10.1126/science.abe1505. Epub 2022 May 27. PubMed PMID: 35617398; PubMed Central PMCID: PMC9299269.


Han H, Wang Y, Curto J, Gurrapu S, Laudato S, Rumandla A, Chakraborty G, Wang X, Chen H, Jiang Y, Kumar D, Caggiano EG, Capogiri M, Zhang B, Ji Y, Maity SN, Hu M, Bai S, Aparicio AM, Efstathiou E, Logothetis CJ, Navin N, Navone NM, Chen Y, Giancotti FG. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Rep. 2022 Apr 5;39(1):110595. doi: 10.1016/j.celrep.2022.110595. PubMed PMID: 35385726.

Mazzu YZ, Liao YR, Nandakumar S, Jehane LE, Koche RP, Rajanala SH, Li R, Zhao H, Gerke TA, Chakraborty G, Lee GM, Nanjangud GJ, Gopalan A, Chen Y, Kantoff PW. <u>Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer.</u> Oncogene. 2022 Jan;41(5):671-682. doi: 10.1038/s41388-021-02118-4. Epub 2021 Nov 20. PubMed PMID: 34802033.

View All Publications

People

The Yu Chen Lab 4/8



Research Technician

Naltao vvang
Senior Research Scientist

Chen Khuan Wong Research Fellow

Lab Alumni

The Yu Chen Lab 5/8

Lab Affiliations

+

Achievements

Louis V. Gerstner Young Investigator Award, Memorial Sloan Kettering Cancer Center (2011)

Young Investigator Award, Prostate Cancer Foundation (2011)

Physician Research Training Award, Department of Defense Prostate Cancer Research Program (2010)

Advanced Fellowship Award, Charles H. Revson Foundation (2009)

K08 Clinical Scientist Development Award, National Institutes of Health (2009)

Read more

+

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now



Get in Touch

Lab Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Yu Chen discloses the following relationships and financial interests:

Merck & Co Inc.

Professional Services and Activities

The Yu Chen Lab 6/8

Myovant Sciences

Equity

Oric Pharmaceuticals

Equity; Intellectual Property Rights

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies <u>here</u>. For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at <u>ecoi@mskcc.org</u>.

View all disclosures





The Yu Chen Lab 7/8

Nutrition & cancer

Find a doctor

Research & Education

Sloan Kettering Institute

Gerstner Sloan Kettering Graduate School

Graduate medical education

MSK Library

Communication preferences

Cookie preferences

Legal disclaimer

Accessibility statement

Privacy policy

Price transparency

Public notices

© 2024 Memorial Sloan Kettering Cancer Center

The Yu Chen Lab 8/8